In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
ID: 357009Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357009

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-140.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for in-depth phenotyping and research using knockout mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Clinical Trial Not Allowed grant mechanism. This initiative aims to encourage applications that leverage the International Mouse Phenotyping Consortium (IMPC) resources to better understand genetic functions related to congenital diseases and structural defects, particularly those affecting embryonic development and fertility. The program is part of a broader effort to catalog mammalian gene function, with an award ceiling of $499,999 per year for projects lasting up to five years. Interested applicants must submit their proposals by January 7, 2026, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-140-Full-Announcement.html
    PAR-25-140.html
    The Department of Health and Human Services is issuing a funding opportunity through the National Institutes of Health (NIH) aimed at in-depth research and phenotyping of embryonic lethal and subviable knockout mouse strains produced by the International Mouse Phenotyping Consortium (IMPC). The initiative, which falls under the R01 Research Project Grant, encourages applications that focus on understanding genetic functions related to congenital diseases and structural defects, including fertility issues linked to embryonic development. Key dates for application submissions range from May 5, 2025, to June 5, 2025, with a project duration of up to five years and budgets of up to $499,999 annually. Interested applicants are urged to adhere to specific NIH guidelines, including a resource-sharing plan for generated data and biospecimens. The existing program, KOMP2, expects an increase in available mouse strains and aims to enhance knowledge critical to gene function in human health. Eligible applicants include various higher education institutions and nonprofit organizations, with an emphasis on inclusion from diverse backgrounds. This opportunity reflects NIH's commitment to advancing biomedical research and improving health outcomes through innovative genetic studies.
    Similar Opportunities
    In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for in-depth phenotyping and research using knockout (KO) mouse strains that exhibit embryonic or perinatal lethality or subviability, under the R01 Research Project Grant mechanism (Funding Opportunity Announcement PAR-23-074). This initiative encourages applications to perform detailed phenotyping on specific KO mouse cohorts or to utilize these strains in hypothesis-driven research related to congenital diseases and fertility issues, contributing to the mission of the International Mouse Phenotyping Consortium (IMPC) to catalog mammalian gene functions. The funding amount can reach up to $499,999 per year for a duration of five years, with applications due by January 7, 2026. Interested applicants can find more information and guidance on the submission process at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This initiative encourages applicants to utilize advancements in genetics, omics methods, and synthetic biology to explore genetic, environmental, and epigenetic factors contributing to these anomalies, which affect approximately 3% of live births in the U.S. The grant allows for budgets up to $499,999 in direct costs per year, with project periods not exceeding five years, and applications are due by February 5, 2025. Interested parties can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)" aimed at advancing research on congenital defects linked to genetic variants. This initiative encourages the use of cutting-edge genotyping and sequencing technologies to validate genetic variants identified through public databases, bridging the gap between variant identification and understanding their functional impacts on developmental outcomes. The funding is available to a diverse range of eligible organizations, including higher education institutions and nonprofits, with an annual budget cap of $499,999 and a project period of up to five years. Interested applicants should contact the NIH OER Webmaster at grantsinfo@nih.gov for assistance and must submit their proposals by May 7, 2025, to be considered for this significant funding opportunity.
    Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the screening and functional validation of genomic variants associated with human congenital anomalies through the R01 Clinical Trial Not Allowed grant. This initiative aims to leverage advancements in genomic technologies to identify and validate genetic variants linked to congenital defects, intellectual developmental disabilities, and inborn errors of metabolism, thereby bridging the gap between genetic identification and functional impact on health. Eligible applicants include a wide range of institutions such as universities, nonprofits, and tribal governments, with a maximum budget of $499,999 per project year and a project duration of up to five years. Interested parties should submit their applications by January 7, 2028, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-185.html for further details.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)," aimed at improving the utility of mammalian cancer models in translational research. This initiative seeks projects that enhance the accuracy and application of models, such as organoids and tumoroids, to better represent human biology and inform clinical practices, addressing current limitations and fostering innovation in cancer research methodologies. Eligible applicants include a diverse range of organizations, such as higher education institutions and community-based organizations, with a maximum funding amount of $499,000 per year for projects not exceeding five years. Interested parties should submit their applications through Grants.gov, with deadlines beginning January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)." This initiative invites applications aimed at improving the utility of mammalian cancer models, including organoids and tumoroids, to better represent human biology and address translational deficiencies in existing models. The funding seeks to advance cancer research by fostering innovative approaches to validate these models and enhance their clinical relevance, ultimately aiming to improve patient outcomes. Eligible applicants can receive up to $499,000 per year for a maximum of five years, with applications due by September 7, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-281.html.
    Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)" aimed at supporting preclinical efficacy studies for therapeutic agents targeting rare diseases. This initiative seeks to fund projects that demonstrate the effectiveness of proposed treatments in established rare disease models, along with necessary pharmacodynamic and pharmacokinetic studies, to facilitate further development towards Investigational New Drug (IND) applications or clinical trials. With a total funding budget of up to $1.2 million, the NIH anticipates awarding 3-5 grants, each with a maximum budget of $275,000 over a two-year project period. Interested applicants must submit letters of intent by May 1, 2024, with full applications due by May 3, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Basic Neurodevelopmental Biology of Circuits and Behavior (R01 Clinical Trial Not Allowed)" aimed at supporting research into the connections between brain circuit maturation and behavioral development in rodents and non-human primates. This initiative seeks to explore how neural interactions evolve during pre- and post-natal development, influencing cognitive, emotional, and social behaviors, with a focus on in vivo neural measures and developmental trajectories from prenatal stages to early adulthood. Grants of up to $500,000 per year are available for a maximum duration of five years, with applications due by January 7, 2025. Interested applicants can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and detailed guidelines are available at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-066.html.
    Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting research project applications for the grant opportunity titled "Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research." This initiative aims to support hypothesis-driven projects that develop technologies and resources to improve the validity and applicability of animal research across multiple organ systems and diseases, addressing critical gaps identified in previous workshops. The funding is crucial for enhancing research methodologies in biomedical applications, with awards available for up to five years and a maximum budget of $500,000, requiring pre-approval for requests exceeding this amount. Interested applicants can find more information and application guidelines at the NIH Grants Information website or contact grantsinfo@nih.gov, with the application deadline set for September 7, 2025.